For more than 45 years, the scientific research community has trusted Bethyl Laboratories and our rigorous antibody validation process. Our scientists manufacture and validate all our antibodies at our lab in Montgomery, Texas, and if a product doesn’t meet our standards, it doesn’t leave our facility.
At Bethyl, reproducibility matters and we understand its role within life science. As a result, we have devised a unique validation process that tests with paired antibodies raised against distinct protein epitopes. Validation is a continuous process at Bethyl, and we routinely evaluate new lots side-by-side with old lots to ensure lot-to-lot consistency.
To pass our antibody validation process, products must meet four distinct criteria:
Our two-phase process ensures that each antibody recognizes distinct epitopes of a target protein.
Our antibody validation process begins with antigen design:
In the second phase of our antibody validation process, we test for specificity and selectivity using the western blot (WB) method in conjunction with immunoprecipitation (IP).
By analyzing western blots of immunoprecipitates, in conjunction with a western blot of the whole-cell lysate, we can verify the mobility of the target protein. Using multiple dilutions and a broad spectrum of whole-cell lysates, our scientists can verify selective binding as well as the antibody’s specificity, reproducibility, and sensitivity.
At the conclusion of this two-phase process, only antibodies exhibiting the following characteristics qualify to be released:
To evaluate antibody selectivity for immunohistochemistry (IHC), we use multiple antibodies generated against distinct epitopes to demonstrate concordance. Valid antibodies will produce similar staining patterns across a range of tissues and cells.
To qualify for utility in IHC, antibodies must exhibit